The COVID-19 Clinical Research Coalition (www.covid19crc.org) was launched by 77 signatories to a Comment in The Lancet in early April 2020. The coalition was formed to support collaboration and solutions to accelerate COVID-19 research in low-resource contexts where the virus could wreak havoc on already-fragile health systems and cause the greatest health impact on vulnerable populations. The coalition brings together individuals and institutions working to fast-track research that will provide evidence on COVID-19 prevention, diagnosis, and case management in resource-limited settings. Since its launch, membership has increased to more than 800 members from 89 countries and 230 institutions.

The COVID-19 Clinical Research Coalition was launched in April 2020 with a Comment in The Lancet and a mission to advocate and collaborate for the advancement of COVID-19 research driven by the needs of resource-limited settings, and for equitable access to proven solutions in the global pandemic response.

The Coalition is currently hosted by the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization that develops new, improved, and affordable medicines for deadly neglected diseases that afflict millions of the world’s poorest people (www.dndi.org).

Description

Since the Coalition’s launch, topic-specific working groups have been convened to tackle a broad spectrum of pandemic-related issues and have identified focused priorities.

The Therapeutics Working Group of the COVID-19 Clinical Research Coalition is a newly formed working group that will provide a platform to discuss urgent considerations for COVID-19 therapeutics in low-resource settings and promotion of relevant research. The overall objectives of the Working Group are to provide:

1. Advisory role for the coalition and extended networks, providing a platform for relevant COVID-19 therapeutics discussions
2. Advocacy role, actively advocating for the therapeutics research that will generate the most relevant evidence for resource-limited settings.

In support of the above objectives, the Coalition is looking for a Therapeutics Review Consultant (1.5 days per week) who will systematically review data or evidence on COVID-19 therapeutics. She/he will be a vital link in the compilation of existing evidence in a weekly summary report, which will be made available to interested researchers and will inform working group discussions and pipeline assessment.

The consultant should be an energetic, self-driven individual willing to continuously seek out current data and evidence for COVID-19 therapeutics. Tasks will include:

- Continuous identification of topic-specific resources relevant for clinical research in low-resource settings to be shared within the working group.
- Systematic screening of COVID-19 therapeutics, clinical trials, and other data sources (e.g., academic databases, online libraries, relevant websites, etc.) to generate information and knowledge on the current and evolving therapeutics landscape.
- Synthesizing findings in a weekly summary report on the output of this systematic evaluation.
- Identification of research gaps and trends in therapeutics for COVID-19, particularly those relevant to low resource settings.
- Working closely with Therapeutics Working Group members to inform their objectives of advocacy, advice, and knowledge generation.
- Other research tasks as agreed within the working group.

This consultancy will formally report to the coalition’s Secretariat, which is hosted by DNDi, but will be guided by the Chair or Co-chairs of the Therapeutics Working Group.

**Note:** Depending on the interest of the selected consultant, this consultancy could be increased to two days per week, with the additional half day per week dedicated to supporting the coordination of the Therapeutics Working Group.

### Consultancy requirements

#### Education & experience:
- Education: a recent graduate or current student, Masters, PhD, or Post-doc level.
- Good knowledge and experience in performing systematic reviews / literature reviews.
- Knowledge and skills in research methodology and their application in clinical trials as well as generation of evidence from real-world data.
- Topic-specific knowledge or experience relevant to COVID-19 therapeutics is an advantage.
- Excellent skills in communication, time management, and multicultural sensitivity.
- Excellent scientific reading and writing skills in English.

#### Other requirements
- Fluency in English required.
- Proficiency in other languages desirable, particularly French, Spanish, or Portuguese.
- Proficiency in Microsoft Office suite of software (Word, Excel, PowerPoint); comfortable with teleconference and other platforms for collaborative work and communication.

### Applying for the consultancy

To apply for this consultancy, please send an email to info@covid19crc.org with your CV and a cover letter explaining your interest and summarizing relevant qualifications and experience. **Application deadline: Monday, 18 April 2022.** Application submission for this position may close early if we have enough suitable applicants.